These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 34181768)

  • 1. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.
    Rho E; Näf B; Müller TF; Wüthrich RP; Schachter T; von Moos S
    Clin Transplant; 2021 Nov; 35(11):e14401. PubMed ID: 34181768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients.
    Jorgenson MR; Descourouez JL; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
    Transpl Infect Dis; 2021 Aug; 23(4):e13693. PubMed ID: 34309158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
    Jorgenson MR; Kleiboeker H; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
    Transpl Infect Dis; 2022 Feb; 24(1):e13766. PubMed ID: 34799964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Case Report of Successful Use of Twice-Daily Letermovir in the Treatment of Resistant Cytomegalovirus in a Small Bowel Transplant Recipient.
    Joharji H; Alaidaros F; Koujan H; Hamad A; Almaghrabi RS; Zidan A; Broering D; Al-Jedai A
    Transplant Proc; 2022; 54(6):1679-1681. PubMed ID: 35842318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
    Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistant Cytomegalovirus Infection After Renal Transplantation: Literature Review.
    Cintra-Cabrera M; Suárez-Benjumea A; Bernal-Blanco G; González-Roncero FM; Toapanta-Gaibor NG; Súñer-Poblet M; Pérez-Valdivia MÁ; Fernández-Cuenca F; Gentil-Govantes MÁ; Rocha-Castilla JL
    Transplant Proc; 2018 Mar; 50(2):575-577. PubMed ID: 29579856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients.
    Razonable RR
    Clin Microbiol Infect; 2023 Sep; 29(9):1144-1149. PubMed ID: 36963566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letermovir for pre-emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation.
    Kaur R; Purtill D; Cooney J; Cannell P; Wright M; Copeland TS; McGuire M; Boan P
    Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14147. PubMed ID: 37676725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letermovir Rescue Therapy in Kidney Transplant Recipients with Refractory/Resistant CMV Disease.
    von Hoerschelmann E; Münch J; Gao L; Lücht C; Naik MG; Schmidt D; Pitzinger P; Michel D; Avaniadi P; Schrezenmeier E; Choi M; Halleck F; Budde K
    J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.
    Cherrier L; Nasar A; Goodlet KJ; Nailor MD; Tokman S; Chou S
    Am J Transplant; 2018 Dec; 18(12):3060-3064. PubMed ID: 30286286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction.
    Jorgenson MR; Descourouez JL; Saddler CM; Smith JA; Odorico JS; Rice JP; Mandelbrot DA
    Clin Transplant; 2023 Dec; 37(12):e15142. PubMed ID: 37755141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
    Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A;
    Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
    Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C
    Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA; Haug Dorenberg D; Kristiansen KI; Rollag H; Leivestad T; Asberg A; Hartmann A
    Transplantation; 2011 Jul; 92(2):217-23. PubMed ID: 21685829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
    Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
    Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.
    Minces LR; Nguyen MH; Mitsani D; Shields RK; Kwak EJ; Silveira FP; Abdel-Massih R; Pilewski JM; Crespo MM; Bermudez C; Bhama JK; Toyoda Y; Clancy CJ
    Antimicrob Agents Chemother; 2014; 58(1):128-35. PubMed ID: 24145525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation.
    Tan CA; Palen L; Su Y; Li Y; Gennarelli RL; Perales MA; Cohen N; Papanicolaou GA; Shah GL; Seo SK
    Transplant Cell Ther; 2024 Aug; 30(8):792.e1-792.e12. PubMed ID: 38838781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of letermovir: a cytomegalovirus prophylactic option.
    Gerna G; Lilleri D; Baldanti F
    Expert Opin Pharmacother; 2019 Aug; 20(12):1429-1438. PubMed ID: 31282759
    [No Abstract]   [Full Text] [Related]  

  • 19. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
    Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
    Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.